2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2017
IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder
Patel AA, Lerner MZ, Blitzer A. IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. Annals Of Otology Rhinology & Laryngology 2017, 126: 328-333. PMID: 28290229, DOI: 10.1177/0003489417693013.Peer-Reviewed Original ResearchConceptsTemporomandibular disordersMuscles of masticationPain scoresTemporomandibular jointSaline injectionMuscle tenderness scoresPreinjection pain scoreAverage pain scorePain medication usageTemporomandibular joint disordersGroup one monthIncobotulinumtoxinA groupsIncobotulinumtoxinA injectionsPain medicationExact pathophysiologyPain scaleSignificant painMedication usageAssociated symptomsJoint disordersMasticatory musclesPainPatientsConventional treatmentMuscle disorders